Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer (Q36456386)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer |
scientific article |
Statements
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer (English)
Michael W Sill
Heather A Lankes
Edgar G Fischer
Andrew K Godwin
Heidi Gray
Russell J Schilder
Joan L Walker
Krishnansu Tewari
Parviz Hanjani
Ovadia Abulafia
Peter G Rose
7 August 2012
1 reference
1 reference
1 reference
1 reference